shutterstock-36383392

NICK BIEMANS / SHUTTERSTOCK.COM

9 June 2016AsiaArchana Shanker

The battle for biotech drugs in India

The Indian biologic market is growing at an annual rate of around 30%. India is therefore seen as a key player in the biosimilar space with an exceptionally high number of approvals granted in the last decade compared to the global average.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

AstraZeneca unit draws line under Samsung dispute

Does the UPC offer a fresh take on patent validity?

Litigation implications of the USPTO’s terminal disclaimer proposal

Ipsen files further suit against CSPC over pancreatic cancer drug generic

Federal Circuit denies rehearing in heart valve case